Embla Medical (EMBLA) Status Update summary

Strategic rationale and acquisition fit

• The acquisition of Fior & Gentz aligns with a five-year strategy to expand reach for chronic mobility impairments, leveraging innovative solutions and creating value for the orthotics and prosthetics (O&P) industry.

• Embla Medical's acquisition of FIOR & GENTZ aligns with its Growth'27 strategy, expanding its portfolio and market reach.

• Fior & Gentz brings a complementary product portfolio, especially in neuro-orthotics, which was previously missing, and offers strong commercial synergies and cultural fit.

• The acquisition is financially accretive, with Fior & Gentz maintaining a high EBITDA margin of around 30%.

• The acquisition is expected to be accretive to Embla's organic sales growth, EBITDA margin, and EPS from 2025.

Company overview

• FIOR & GENTZ, founded in 1997 in Germany, employs around 100 people and specializes in innovative neuro orthotic solutions for chronic neurological conditions.

• The neuro orthotic market is significantly underserved and lags prosthetics by over a decade in innovation and awareness.

Product innovation and market positioning

• Fior & Gentz specializes in custom-made orthoses, focusing on advanced ankle and knee joints, including bionic and microprocessor-controlled devices.

• Portfolio includes advanced knee and ankle joints, such as the NEURO HITRONIC bionic knee joint, offering microprocessor-controlled support.

• The company’s 360-degree Orthotic Concept and open-source configurator tool streamline patient assessment and component selection, enabling over 500,000 possible configurations tailored to patient data.

• Orthoses are highly customizable, adapting to individual patient needs and providing enhanced safety and mobility.

• Annual product launches, especially in bionic solutions, drive ongoing innovation and market leadership.